201 related articles for article (PubMed ID: 12771946)
21. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.
Lu ZY; Condomines M; Tarte K; Nadal L; Delteil MC; Rossi JF; Ferrand C; Klein B
Exp Hematol; 2007 Mar; 35(3):443-53. PubMed ID: 17309825
[TBL] [Abstract][Full Text] [Related]
22. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma.
Fleischer B; Schulze-Bergkamen H; Schuchmann M; Weber A; Biesterfeld S; Müller M; Krammer PH; Galle PR
Int J Oncol; 2006 Jan; 28(1):25-32. PubMed ID: 16327976
[TBL] [Abstract][Full Text] [Related]
23. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC
Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083
[TBL] [Abstract][Full Text] [Related]
24. Mcl-1.
Michels J; Johnson PW; Packham G
Int J Biochem Cell Biol; 2005 Feb; 37(2):267-71. PubMed ID: 15474972
[TBL] [Abstract][Full Text] [Related]
25. Human oral cancers have altered expression of Bcl-2 family members and increased expression of the anti-apoptotic splice variant of Mcl-1.
Mallick S; Patil R; Gyanchandani R; Pawar S; Palve V; Kannan S; Pathak KA; Choudhary M; Teni TR
J Pathol; 2009 Feb; 217(3):398-407. PubMed ID: 19009587
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia selects for high-metastatic Lewis lung carcinoma cells overexpressing Mcl-1 and exhibiting reduced apoptotic potential in solid tumors.
Koshikawa N; Maejima C; Miyazaki K; Nakagawara A; Takenaga K
Oncogene; 2006 Feb; 25(6):917-28. PubMed ID: 16247470
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
Chetoui N; Sylla K; Gagnon-Houde JV; Alcaide-Loridan C; Charron D; Al-Daccak R; Aoudjit F
Mol Cancer Res; 2008 Jan; 6(1):42-52. PubMed ID: 18234961
[TBL] [Abstract][Full Text] [Related]
28. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.
Puthier D; Derenne S; Barillé S; Moreau P; Harousseau JL; Bataille R; Amiot M
Br J Haematol; 1999 Nov; 107(2):392-5. PubMed ID: 10583232
[TBL] [Abstract][Full Text] [Related]
29. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1.
Maurer U; Charvet C; Wagman AS; Dejardin E; Green DR
Mol Cell; 2006 Mar; 21(6):749-60. PubMed ID: 16543145
[TBL] [Abstract][Full Text] [Related]
30. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.
Opferman JT; Letai A; Beard C; Sorcinelli MD; Ong CC; Korsmeyer SJ
Nature; 2003 Dec; 426(6967):671-6. PubMed ID: 14668867
[TBL] [Abstract][Full Text] [Related]
31. Study on the growth inhibition of human multiple myeloma cells by an IL-6Ralpha mutant.
Duan J; Cai X; Wang L; Zhang S; Wang J
IUBMB Life; 2000 Jan; 49(1):23-5. PubMed ID: 10772337
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases.
Hausherr A; Tavares R; Schäffer M; Obermeier A; Miksch C; Mitina O; Ellwart J; Hallek M; Krause G
Oncogene; 2007 Jul; 26(34):4987-98. PubMed ID: 17310994
[TBL] [Abstract][Full Text] [Related]
33. Knockdown of p53 levels in human keratinocytes accelerates Mcl-1 and Bcl-x(L) reduction thereby enhancing UV-light induced apoptosis.
Chaturvedi V; Sitailo LA; Qin JZ; Bodner B; Denning MF; Curry J; Zhang W; Brash D; Nickoloff BJ
Oncogene; 2005 Aug; 24(34):5299-312. PubMed ID: 15940268
[TBL] [Abstract][Full Text] [Related]
34. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2.
Rahaman SO; Vogelbaum MA; Haque SJ
Cancer Res; 2005 Apr; 65(7):2956-63. PubMed ID: 15805299
[TBL] [Abstract][Full Text] [Related]
35. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
Thallinger C; Wolschek MF; Maierhofer H; Skvara H; Pehamberger H; Monia BP; Jansen B; Wacheck V; Selzer E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4185-91. PubMed ID: 15217956
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-6 inhibits apoptosis of malignant plasma cells.
Lichtenstein A; Tu Y; Fady C; Vescio R; Berenson J
Cell Immunol; 1995 May; 162(2):248-55. PubMed ID: 7743552
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation.
Brocke-Heidrich K; Kretzschmar AK; Pfeifer G; Henze C; Löffler D; Koczan D; Thiesen HJ; Burger R; Gramatzki M; Horn F
Blood; 2004 Jan; 103(1):242-51. PubMed ID: 12969979
[TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.
Jourdan M; Tarte K; Legouffe E; Brochier J; Rossi JF; Klein B
Eur Cytokine Netw; 1999 Mar; 10(1):65-70. PubMed ID: 10210775
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-10 induces interleukin-11 responsiveness in human myeloma cell lines.
Lu ZY; Gu ZJ; Zhang XG; Wijdenes J; Neddermann P; Rossi JF; Klein B
FEBS Lett; 1995 Dec; 377(3):515-8. PubMed ID: 8549788
[TBL] [Abstract][Full Text] [Related]
40. MCL-1V, a novel mouse antiapoptotic MCL-1 variant, generated by RNA splicing at a non-canonical splicing pair.
Kojima S; Hyakutake A; Koshikawa N; Nakagawara A; Takenaga K
Biochem Biophys Res Commun; 2010 Jan; 391(1):492-7. PubMed ID: 19919825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
